Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
This article was originally published in The Pink Sheet Daily
Executive Summary
The diabetes drug maker has reportedly spurned a buyout offer at a 43% premium, driving up its share price – and perhaps discouraging it from pursuing the partnership it seeks.
You may also be interested in...
Intarcia Forgoes Partnerships, Raises $210M In Equity And Debt Instead
Rather than partner its implantable formulation of exenatide, the biotech turned to hedge funds and other non-traditional investors for the year’s largest round of private capital. The deal enables Intarcia to begin Phase III trials on lead program ITCA-650 for type 2 diabetes, which it believes could be a blockbuster.
Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin
Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.
Deals Of The Week: Express Scripts/Walgreens, Par/TPG, Amicus/GSK
Following the clinical trial failure of cancer candidate saridegib, Infinity takes back partnered assets from Purdue and plans to go it alone in the PI3K space.